Skip to main content

Table 1 Patients’ characteristics and clinical outcome

From: Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial

Case

Age (years)

Gender

Dose of Pex

Adverse events

Acute inflammatory reaction (site)

1

36

Male

150 mg/d

None

None

2

26

Male

200 mg/d

None

M-7 m (right proximal thigh)

3

18

Female

75 mg/d

None

M-8 m (left hip), D-2 m (right jaw)

4

18

Female

14 mg/d

None

None

5

19

Male

100 mg/d

None

None

  1. Pex = Perhexiline maleate; M-7 m = Medication phase at 7 months.
  2. M-8 m = Medication phase at 8 months; D-2 m = Discontinuation phase at 2 months.